Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells.
Jiang Y, Liu L, Jiang Y, Li Z, Feng L, Zhuang X, Lin Z, Chen Q, Chen G, He J, Li G, Zha J, Xu B.
Jiang Y, et al. Among authors: xu b.
Pharmaceuticals (Basel). 2022 Oct 25;15(11):1313. doi: 10.3390/ph15111313.
Pharmaceuticals (Basel). 2022.
PMID: 36355485
Free PMC article.